---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-23-001612"
form_type: "8-K"
ticker: "ALZN"
cik: "0001677077"
company_name: "Alzamend Neuro, Inc."
filed_at: "2023-02-03T23:59:59+00:00"
generated_at: "2026-06-20T01:10:06.158247+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Alzamend Neuro receives Nasdaq deficiency notice for bid price below $1.00

## Summary
- Received Nasdaq deficiency letter on Jan 30, 2023 for bid price below $1.00 for 30 consecutive days.
- Has 180 calendar days (until July 31, 2023) to regain compliance by closing at $1.00 for 10 consecutive business days.
- May request an additional 180-day compliance period if it meets other listing standards.
- No immediate effect on listing; common stock continues trading on Nasdaq under symbol ALZN.
- Company intends to monitor bid price and evaluate options to regain compliance, but cannot assure success.

## SEC filing metadata
- accession: 0001214659-23-001612
- form_type: 8-K
- ticker: ALZN
- cik: 0001677077
- company_name: Alzamend Neuro, Inc.
- filed_at: 2023-02-03T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677077/000121465923001612/0001214659-23-001612-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677077/000121465923001612/d1312308k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-23-001612
- JSON: https://secwatch.observer/filing/0001214659-23-001612.json
- Plain text: https://secwatch.observer/filing/0001214659-23-001612.txt

## Key facts
- Listing & Compliance Notices
  Alzamend Neuro, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: January 30, 2023, Alzamend Neuro, Inc. (the “Company”) received a notice in the form of a letter (“Deficiency Letter”) from the Listing Qualifications Staff of the Nasdaq stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company’s common stock had closed below $1.00 per share for the previous 30 consecutive business days. In accordance with Nasdaq listing rule 5810(c)(3)(A), the Company has 180 calendar days, or until July 31, 2023, to regain compliance. The Deficiency Letter states that to regain compliance, the bid price for the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1677077/000121465923001612/0001214659-23-001612-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.